ArticleInsights into imaging2026
Predicting intrahepatic recurrence of colorectal cancer liver metastases after curative hepatectomy using a machine learning model with data integration of ultrasound radiomics and clinicopathological parameters.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo develop and validate a machine learning model integrating ultrasound radiomics and clinicopathological parameters to predict intrahepatic recurrence in colorectal cancer liver metastases (CRLM) patients after curative hepatectomy. MATERIALS AND
methodsThis retrospective study enrolled 278 eligible CRLM patients (age, 55 ± 12 years; male, 188) from two centers, including a main cohort (n = 224, July 2010-February 2021) and an external cohort (n = 54, February 2015-October 2020). Patients were stratified by recurrence status during a 2-year follow-up. Preoperative ultrasound images and clinicopathological parameters were collected. Radiomics features were extracted from liver metastases, peri-tumor areas, and disease-free liver parenchyma. Using least absolute shrinkage and selection operator (LASSO) analysis and support vector machine algorithms, three predictive models were developed: clinical, radiomics, and clinical-radiomics combined (cRadiomics) models. Model performance was assessed using five-fold cross-validation (main cohort) and external validation (external cohort), with metrics including receiver operating characteristic (ROC) curve, the area under the ROC curve (AUC), accuracy, sensitivity, and specificity.
resultsSix clinical parameters (pathological lymph node positivity, synchronous liver metastases, bilobar liver metastases, preoperative chemotherapy, use of targeted drugs, and preoperative CA19-9 > 200 U/mL) and seven radiomics features were identified as strong predictors. The cRadiomics model achieved AUC values of 0.811 (95% CI: 0.755-0.861) and 0.784 (95% CI: 0.644-0.880) during testing on the main cohort and external cohort data, respectively, significantly outperforming both radiomics (AUC 0.744 and 0.724; p < 0.01) and clinical models (AUC 0.706 and 0.696; p < 0.05).
conclusionsThe cRadiomics model, integrating ultrasound radiomics and clinicopathological parameters, improved the prediction of intrahepatic recurrence within two years for colorectal liver metastases after curative hepatectomy. CRITICAL RELEVANCE STATEMENT: The cRadiomics model, with enhanced accuracy in predicting intrahepatic recurrence of colorectal liver metastases after curative hepatectomy, holds great potential to improve clinical decision-making and enable personalized management and risk-adapted follow-up for colorectal cancer liver metastases (CRLM) patients. KEY POINTS: The cRadiomics model can predict intrahepatic recurrence of colorectal cancer liver metastases (CRLM) after curative hepatectomy. Machine learning with data integration of ultrasound radiomics and clinicopathological parameters enables better prediction of intrahepatic recurrence for CRLM after curative hepatectomy. The developed model holds great potential to improve clinical decision-making and personalized management for CRLM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.